Continuous glucose monitoring (CGM) technology has evolved over the past decade with
the integration of various devices including insulin pumps, connected insulin pens (CIPs) …

BACKGROUND The glycemic control of automated insulin delivery (AID) systems in
outpatient children and adolescents with type 1 diabetes (T1D) has not been systematically …

Aim To evaluate the efficacy of intermittent short‐term use of a real‐time continuous glucose
monitoring (RT‐CGM) system in non‐insulin–treated patients with type 2 diabetes (T2D) …

Aim To evaluate the efficacy and safety of a dual‐hormone artificial pancreas (DH) in type 1
diabetes. Material and Methods PubMed, Embase, the Cochrane Library and ClinicalTrials …

Abstract The National Institute for Clinical Excellence updated guidance for continuous
glucose monitoring (CGM) in 2022, recommending that CGM be available to all people …

Aim To evaluate the real‐world effectiveness of automated insulin delivery (AID) systems in
patients with type 1 diabetes (T1D). Materials and Methods PubMed, Embase, the Cochrane …

To achieve a fully automatic artificial pancreas (AP), ie, an AP without the need for meal
announcements, the intraperitoneal (IP) route is explored. This route has faster dynamics …

In addition to meal intake, a diabetes system has a feedback behavior to balance the
constituents of the chemicals, which causes instability. Therefore, a search for a feedback …

Research in the treatment of type 1 diabetes has been addressed into two main areas: the
development of “intelligent insulins” capable of auto-regulating their own levels according to …

Background: Hybrid closed-loop control of glucose levels in people with type 1 diabetes
mellitus (T1D) is limited by the requirements on users to manually announce physical activity …